Abstract
Acute coronary syndromes are a frequent cause of hospital admission for patients with coronary artery disease. The pathophysiology of acute coronary syndromes often involves plaque rupture or fissure with platelet aggregation. Recognition of the importance of platelet aggregation resulted in several large randomized trials testing 3 types of platelet antagonists, aspirin, glycoprotein IIb/IIIa inhibitors, and adenosine diphosphate inhibitors. A thorough understanding of the data, risks, and benefits of these therapies is important to optimize treatment of the patient with an acute coronary syndrome. Recognition that there is a great deal of interpatient variability in response to these antiplatelet therapies highlights the need for future research in this area.
Publication types
-
Case Reports
-
Clinical Conference
MeSH terms
-
Adrenergic beta-Antagonists / therapeutic use
-
Angioplasty, Balloon, Coronary
-
Aspirin / therapeutic use
-
Clopidogrel
-
Coronary Artery Bypass
-
Coronary Artery Disease / diagnosis
-
Coronary Artery Disease / therapy
-
Coronary Thrombosis / diagnosis
-
Coronary Thrombosis / therapy
-
Drug Therapy, Combination
-
Electrocardiography
-
Eptifibatide
-
Heparin / therapeutic use
-
Humans
-
Male
-
Middle Aged
-
Myocardial Ischemia / drug therapy*
-
Myocardial Ischemia / physiopathology*
-
Nitroglycerin / therapeutic use
-
Peptides / therapeutic use
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
-
Risk Assessment
-
Stents
-
Ticlopidine / analogs & derivatives*
-
Ticlopidine / therapeutic use
-
Vasodilator Agents / therapeutic use
Substances
-
Adrenergic beta-Antagonists
-
Peptides
-
Platelet Aggregation Inhibitors
-
Platelet Glycoprotein GPIIb-IIIa Complex
-
Vasodilator Agents
-
Heparin
-
Clopidogrel
-
Nitroglycerin
-
Eptifibatide
-
Ticlopidine
-
Aspirin